Please Wait
Applying Filters...

End Use API: CAS 103577-40-8

Filters
×

filter

ENAL DRUGS PRIVATE LIMITED

Srini Pharmaceuticals Ltd.

Request an Update of Your Company Information, Events & Sales Content

CAS Number

103577-40-8

End Use API

Lansoprazole

Supporting Information

View All Icon

About the Company

Enal Drugs Private Limited,an ISO 9001 : 2000...

Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other active pharmaceutical ingredients (APIs) and intermediates. The project implementation commenced in the year 1990. Experimental batches in pilot plant were undertaken and commercial production started in the year 1996. The promoters are first generation entrepreneurs with high technical qualifications, professional experience and leadership qualities team spirit and confidence to make this activity a successful business venture. In the field of exports , Enal Drugs Private Ltd. enjoys a considerable reputation and export is the key thrust area of the company and is given maximum attention. The countries to which Enal Drugs Private Ltd. exports its products include Europe, Asia, Africa & South American countries. The company is professionally managed having its corporate head quarters and works strategically situated in Hyderabad city, the heart of bulk drug manufacturing activity in India. The administration, marketing, sales, purchase, finance & accounts divisions are housed in the manufacturing site.

Request an Update of Your Company Information, Events & Sales Content

CAS Number

103577-40-8

End Use API

Lansoprazole

Supporting Information

View All Icon

About the Company

Srini is a US-FDA and TGA approved pharmace...

Srini is a US-FDA and TGA approved pharmaceutical company located near Hyderabad, South India. We at Srini are actively engaged in the exports of Active Pharmaceutical Ingredients (APIs) and (N-1) drug intermediates to Regulatory and Non-Regulatory markets. The facility has five full-fledged production blocks with the efficient utilities such as steam, chilled water, nitrogen generation, cooling water, vacuum and compressed air supply. It has state-of-the-art centralized quality control and R&D Lab. The total capacity of the plant is 276 KL with Ten independent class 100,000 clean room areas to produce 360MT of APIs and 640MT of Intermediates per annum.

PharmaCompass >>

First
Previous
Next
Last